Neurocrine Biosciences reported $169.5M in Loan Capital for its fiscal quarter ending in March of 2023.





Loan Capital Change Date
AbbVie USD 62.48B 2.05B Jun/2026
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 1.47B 5.38M Sep/2026
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
Amgen USD 51.61B 250M Sep/2026
Biogen USD 7.29B 1.7M Sep/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Cytokinetics USD 244.33M 3.87M Sep/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 23.82B 17M Sep/2026
Halozyme Therapeutics USD 2.94B 1.01B Sep/2026
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 60B 498M Sep/2026
Prothena USD 0 0 Dec/2024
Regeneron Pharmaceuticals USD 1.99B 400K Sep/2026
Repligen USD 555.6M 4.55M Sep/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
Teva Pharmaceutical Industries USD 12.68B 588M Sep/2026
Ultragenyx Pharmaceutical USD 1.13B 2M Jun/2026
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026